Serina Therapeutics said it has enrolled the first patient in a global Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease. The study will evaluate safety, tolerability, pharmacokinetics and preliminary efficacy in patients whose symptoms are inadequately controlled by standard therapies, with first dosing expected in the first quarter of 2026. No trial results have been presented yet; the company said it will provide updates as enrollment progresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657395-en) on February 19, 2026, and is solely responsible for the information contained therein.